Literature DB >> 22198020

Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.

P Mulcahy1, A O'Doherty, A Paucard, T O'Brien, D Kirik, E Dowd.   

Abstract

Modeling Parkinson's disease remains a major challenge for preclinical researchers, as existing models fail to reliably recapitulate all of the classic features of the disease, namely, the progressive emergence of a bradykinetic motor syndrome with underlying nigrostriatal α-synuclein protein accumulation and nigrostriatal neurodegeneration. One limitation of the existing models is that they are normally induced by a single neuropathological insult, whereas the human disease is thought to be multifactorial with genetic and environmental factors contributing to the disease pathogenesis. Thus, in order to develop a more relevant model, we sought to determine if administration of the Parkinson's disease-associated pesticide, rotenone, into the substantia nigra of rats overexpressing the Parkinson's disease-associated protein, α-synuclein, could reliably model the triad of classic features of the human disease. To do so, rats underwent stereotaxic surgery for unilateral delivery of the adeno-associated virus (AAV)-α-synuclein into the substantia nigra. This was followed 13 weeks later by delivery of rotenone into the same site. The effect of the genetic and environmental insults alone or in combination on lateralised motor performance (Corridor, Stepping, and Whisker Tests), nigrostriatal integrity (tyrosine hydroxylase immunohistochemistry), and α-synucleinopathy (α-synuclein immunohistochemistry) was assessed. We found that rats treated with either AAV-α-synuclein or rotenone developed significant motor dysfunction with underlying nigrostriatal neurodegeneration. However, when the genetic and environmental insults were sequentially administered, the detrimental impact of the combined insults on motor performance and nigrostriatal integrity was significantly greater than the impact of either insult alone. This indicates that sequential exposure to relevant genetic and environmental insults is a valid approach to modeling human Parkinson's disease in the rat.
Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198020     DOI: 10.1016/j.neuroscience.2011.12.011

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  15 in total

1.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

2.  RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.

Authors:  Elaine L Pranski; Nirjari V Dalal; Carson Van Sanford; Jeremy H Herskowitz; Marla Gearing; Carlos Lazo; Gary W Miller; James J Lah; Allan I Levey; Ranjita S Betarbet
Journal:  Neurobiol Dis       Date:  2013-01-11       Impact factor: 5.996

3.  Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.

Authors:  Joseph R Patterson; Megan F Duffy; Christopher J Kemp; Jacob W Howe; Timothy J Collier; Anna C Stoll; Kathryn M Miller; Pooja Patel; Nathan Levine; Darren J Moore; Kelvin C Luk; Sheila M Fleming; Nicholas M Kanaan; Katrina L Paumier; Omar M A El-Agnaf; Caryl E Sortwell
Journal:  Neurobiol Dis       Date:  2019-07-02       Impact factor: 5.996

4.  Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.

Authors:  Annadurai Anandhan; Humberto Rodriguez-Rocha; Iryna Bohovych; Amy M Griggs; Laura Zavala-Flores; Elsa M Reyes-Reyes; Javier Seravalli; Lia A Stanciu; Jaekwon Lee; Jean-Christophe Rochet; Oleh Khalimonchuk; Rodrigo Franco
Journal:  Neurobiol Dis       Date:  2014-12-08       Impact factor: 5.996

5.  Psychological Stress Phenocopies Brain Mitochondrial Dysfunction and Motor Deficits as Observed in a Parkinsonian Rat Model.

Authors:  Mariana Grigoruţă; Alejandro Martínez-Martínez; Raul Y Dagda; Ruben K Dagda
Journal:  Mol Neurobiol       Date:  2019-12-14       Impact factor: 5.590

Review 6.  Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention.

Authors:  Ying Wang; Wenli Ma; Wenling Zheng
Journal:  Mol Clin Oncol       Date:  2012-10-18

Review 7.  Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.

Authors:  Erwan Bezard; Zhenyu Yue; Deniz Kirik; Maria Grazia Spillantini
Journal:  Mov Disord       Date:  2012-07-02       Impact factor: 10.338

8.  Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.

Authors:  Sara E Gombash; Fredric P Manfredsson; Christopher J Kemp; Nathan C Kuhn; Sheila M Fleming; Ann E Egan; Laura M Grant; Michelle R Ciucci; Jeffrey P MacKeigan; Caryl E Sortwell
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

9.  Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.

Authors:  D Luke Fischer; Fredric P Manfredsson; Christopher J Kemp; Allyson Cole-Strauss; Jack W Lipton; Megan F Duffy; Nicole K Polinski; Kathy Steece-Collier; Timothy J Collier; Sara E Gombash; Daniel J Buhlinger; Caryl E Sortwell
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

10.  Intermittent Fasting Applied in Combination with Rotenone Treatment Exacerbates Dopamine Neurons Degeneration in Mice.

Authors:  Giuseppe Tatulli; Nico Mitro; Stefano M Cannata; Matteo Audano; Donatella Caruso; Giovanna D'Arcangelo; Daniele Lettieri-Barbato; Katia Aquilano
Journal:  Front Cell Neurosci       Date:  2018-01-17       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.